Pharvaris N.V. shares fall 4.98% in after-hours after updating key study data release timeline to Q4 2025.
ByAinvest
Friday, Jul 11, 2025 5:50 pm ET1min read
PHVS--
Pharvaris N.V. plunged 4.98% in after-hours trading, following the company's announcement that it has updated the release date for the topline data from its pivotal Phase 3 RAPIDe-3 study to the fourth quarter of 2025, with plans to submit a new drug application to the FDA in the first half of 2026, assuming positive data. The company is a late-stage biopharmaceutical company focused on developing oral therapies for rare diseases mediated by bradykinin, including deucrictibant for hereditary angioedema.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet